Investment Banking

The Quarterly Rx: Q1 2024 U.S. Biopharma Recap

Biopharma’s rebound came into full effect in Q1 2024. Major biopharma indices extended their year-end rally helping lay the foundation for an extremely active quarter for public financings with 105 total offerings (including IPOs, follow-ons, PIPEs and RDs), raising a total of $18.7 billion. Both totals were the highest since the first quarter of 2021. Additionally, the private financing market skewed later-stage and “crossovers” became more common thanks to a reopening IPO window.

Meanwhile, big pharma’s appetite for deal making continued with eight acquisitions announced over $1 billion in deal value and 10 partnering deals announced with more than $50 million in upfront proceeds this quarter. Although, some market participants worry the recovery has been too swift, and the U.S. presidential election looms large for overall market health, the stage remains set for a much more favorable 2024 for biopharma.

William Blair's biopharma team shares additional perspectives on the biopharma environment in Q1 2024 and what to expect for the remainder of the year.

Complete the form below to download a copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

More News and Insights

AviationPros Podcast: Addressing Trends and Concerns in the FBO Industry

Josh Ollek, managing director of William Blair’s Aerospace, Defense, and Government Services team, recently joined the AviationPros Podcast. Ollek discussed how high demand for private aviation—spurred by persistent delays and cancellations on commercial flights—has created a hangar shortage across the country. He also outlined electrification trends in private travel and among fixed-base operators.

Listen to the podcast

Buyers Edge Platform Has Received a Preferred Equity Investment Led by General Atlantic Credit’s Atlantic Park Fund, Alongside Blackstone Tactical Opportunities and Morgan Stanley Tactical Value

William Blair served as a placement agent to Buyers Edge Platform, a portfolio company of Bregal Sagemount, in connection with its $425 million preferred equity investment led by General Atlantic Credit’s Atlantic Park fund, alongside funds managed by Blackstone Tactical Opportunities and investment funds managed by Morgan Stanley Tactical Value.

Read more

Understanding Increasingly Popular Holdco NAV Structures

NAV financing—loans to funds supported by the net asset value of their portfolios—has become increasingly popular with financial sponsors over the past year. This article, written in partnership with global law firm Proskauer Rose, outlines how the Holdco Structure helps navigate key considerations in NAV financings.

Read more

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit